## Microbiome-based biomarkers to guide personalized microbiome-

- based therapies for Parkinson's disease. 2
- Haydeh Payami\* 1,2, Timothy R Sampson 2,3, Charles F Murchison 1,2,4 4
- <sup>1</sup> Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA 6
- 7 <sup>2</sup> Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase,
- 8 MD. 20815. USA
- 9 <sup>3</sup> Department of Cell Biology, Emory University, Atlanta, GA, 30329, USA
- 10 <sup>4</sup> Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 35233,
- 11 USA

12

19

1

3

5

- 13 \*Senior and Corresponding author:
- 14 Haydeh Payami, PhD
- 15 University of Alabama at Birmingham, Room 429, Civitan International Research Center, 1719
- 16 6th Ave S, Birmingham, AL 35233
- 17 Phone: 205-994-1909
- 18 Email: haydehpayami@uabmc.edu
- 20 Running title: Microbiome-based biomarkers
- 21 Word count: Abstract 125. Introduction 448. Method 995. Results 610. Discussion 867.
- 22 32 references. 2 Tables. 3 Figures.

## **Abstract**

We address an unmet challenge in Parkinson's disease: the lack of biomarkers to identify the right patients for the right therapy, which is a main reason clinical trials for disease modifying treatments have all failed. We present the gut microbiome as a target for treatment and introduce microbiome-based biomarkers to guide personalized treatments. We show that not all persons with PD have a dysbiotic microbiome, and not all dysbiotic PD microbiomes have the same features. We have developed an intuitive and easily modifiable method to identify the optimal candidates for microbiome-based clinical trials, and subsequently, for treatments that are personalized for each individual's dysbiotic features. We demonstrate the method for PD. The concept, and the method, is generalizable for any disease with a microbiome component.

## Introduction

Parkinson's disease (PD) is the fastest growing neurologic disease in the world <sup>1</sup>. PD is a progressively debilitating disease <sup>2</sup>. The earliest manifestations are often constipation, sleep disorder, and hyposmia, leading to the cardinal movement disorders, and as disease progresses, most patients develop psychosis and dementia. Treatments are symptomatic. There have been many clinical trials for disease modifying treatment aimed at stopping disease progression, and all have failed (clinicaltrials.gov). PD is a highly heterogenous disease. One treatment will not work for all patients. Biomarkers to guide selection of the right patients for the right drug has been a high-priority, unmet need.

It has long been known that constipation, inflammation in the gut, and permeable gut membrane are common in PD and precede motor signs <sup>2</sup>. Recent studies suggest some cases of PD start in the gut and spread to the brain, and in rodent models, PD pathologies are observed to spread from gut to brain <sup>3-7</sup>. The gut origin raised the possibility that the gut microbiome could be involved in the brain-gut-axis pathology of PD. A healthy gut microbiome controls metabolism of drugs, toxicants and food, synthesis of vitamins and neurotransmitters, keeps the lining of the gut intact, protects against pathogens, maintains the proper functioning of the immune and nervous systems, and modulates brain-gut communication <sup>8</sup>.

It is becoming increasing clear that the gut microbiome is severely dysbiotic in PD <sup>9-11</sup>, with features that could directly affect initiation and progression of PD. Dysbiotic features of PD microbiome are relevant to multiple PD mechanisms <sup>9</sup>, including increased abundance of pathogens and immunogens, decreased production of neuroactive molecules (dopamine, serotonin, glutamate and GABA), reduced capacity to degrade plant-based fiber which leads to short chain fatty acids deficiency, increased inflammation and compromised gut barrier, and elevated *E. coli* and curli. Curli is a bacterial amyloid produced by *E.coli* which, in mice, induces alpha-synuclein aggregation, the hallmark of PD pathology <sup>12,13</sup>. Data from genetic and toxicant-induced models of PD also suggest gut microbiome can trigger or contribute to various PD pathologies and the manifestation of motor and non-motor phenotypes <sup>14-17</sup>, and that altering the microbiome via fecal microbiome transplantation (FMT)<sup>18,19</sup>, antibiotics treatments<sup>20-23</sup>, or high fiber diet<sup>24</sup>, each to some extent can reduce alpha-synuclein pathology, inflammation, and motor and non-motor dysfunction.

The gut microbiome is an emerging target for PD therapies <sup>25,26</sup>. Results of early clinical trials with fiber supplementation <sup>27</sup> and FMT <sup>28-31</sup> are promising. Next-generation targeted therapeutics are forthcoming. Here, we show that not all PD patients have a dysbiotic microbiome and not all dysbiotic microbiomes have the same features. We introduce microbiome-based biomarkers to guide patient selection for clinical trials, and upon success, as companion diagnostic for personalized treatment.

## The Method

#### **Overview**

The overview of the method is shown in **Figure 1**. The concept and method are generalizable to any disorder with a microbiome component, here, we fcus on PD. The method requires a metagenomics reference dataset from older adults without PD. Non-PD individuals should be from the same population as the patients to be studied or treated (such reference datasets will soon be available for several populations). We select features of interest as potential targets for treatment. Features can be a single gene or metabolite, a species, a cluster of related species, or multiple polymicrobial clusters that are being targeted for treatment. We then calculate the mean relative abundance and confidence intervals (CI) of the features in the metagenomics dataset of older adults without PD. We have now created the reference dataset. We define

dysbiosis by setting thresholds for relative abundances in reference dataset (e.g., outside 95% CI). Patients can now be screened for dysbiotic features, which entails obtaining a stool sample, metagenomic sequencing and comparing the relative abundance of the features in the patient to the reference dataset and the thresholds that define dysbiosis.

#### Foundation of the method

We previously conducted a large-scale high-resolution metagenomic analysis, where we mapped the dysbiotic features of PD microbiome <sup>9</sup>. Results were published and all data and protocols are open access without restriction (see Data Availability). The dataset is composed of deep-shotgun next-generation metagenome sequences of microbial DNA, extracted from stool samples of 490 individuals with PD and 234 neurologically healthy controls (NHC). We conducted a metagenome-wide association study (MWAS) and identified species, genes and pathways that are depleted or overly abundant in PD. We also conducted correlations network analysis (using SparCC) and identified polymicrobial clusters of species whose abundances grow or shrink together <sup>9</sup>. The visual of PD microbiome network and its clusters resembles and thus is called Fireworks (**Figure 2**).

### The concept

The published study <sup>9</sup> was microbiome-centric, i.e., we identified dysbiotic features in aggregates of patients as compared to NHC. We now turn the approach around and make it individual-centric, i.e., what does the microbiome in a given patient look like? Is the microbiome dysbiotic in every PD patient? Are all dysbiotic features present together, or are some features present in a subset of patients, and if so, what percentage of patients has a given dysbiotic feature? The answers to these questions are fundamental to any microbiome-based therapeutic. To answer these questions, we had to (a) select features of interest that could potentially be a target of treatment and (b) create an operational definition of dysbiosis. The concept is generalizable, and the method, both feature selection and definition of dysbiosis, can be modified to accommodate study design.

### Features of PD gut microbiome

For feature selection, we used the data reported in Wallen et al <sup>9</sup>. We selected species that were significantly associated with PD (i.e., their abundance was elevated or reduced in PD) <sup>9</sup>, plus the cluster of rare opportunistic pathogens, which were too rare to be tested individually, but form a polymicrobial cluster that was shown in two independent datasets to be elevated in PD <sup>9,32</sup>. We grouped the selected PD-associated species into six features based on the correlation in their abundances (|r|>0.2, P<0.05) and taxonomic relatedness (members of same genus). The six dysbiotic features (**Table 1, Figure 2**) are as follows: (1) the cluster of opportunistic pathogens (elevated in PD), (2) species of *Bifidobacteria* (elevated in PD), (3) species of *Lactobacillus* (elevated in PD), (4) *Streptococcus* and *Actinomyces* species that are elevated in PD, (5) *E. coli* and *Klebsiella species* that are elevated in PD, and (6) fiber-degrading bacteria (reduced in PD). There is more to the dysbiosis of PD gut than these six features <sup>9</sup>. The features can be redefined to accommodate the aims of the investigation. Here, we strived for a balance between minimizing complexity while capturing the most robust and biologically relevant features. The aim was to demonstrate the method behind microbiome-based biomarkers.

## **Definition of dysbiotic and non-dysbiotic**

We needed a working definition of dysbiotic. First step is to optimize patient selection for clinical trials. To that end, we set high thresholds for defining dysbiosis in order to maximize the odds that the patient being enrolled is an optimal candidate. These thresholds can be changed to accommodate study design, or relaxed when a drug is approved, and the biomarkers become companion diagnostics for personalized treatment.

For each feature, and per person, we calculated total relative abundance of each feature by summing the relative abundances of the species within it. We then calculated the mean relative abundance and its 95% CI in NHC (reference dataset). Next, we turned to individual-level PD data. Considering each feature separately, we called a PD person's metagenome dysbiotic if the relative abundance of the feature was outside the 95% CI of NHC. For features that are elevated in PD in aggregate data, a PD individual's gut was called dysbiotic if the relative abundance of the feature in that person was greater than the upper bound of 95% CI of NHC. For the feature that is reduced in PD, a PD individual's microbiome was called dysbiotic if the relative abundance of the feature in that person was less than the lower bound of 95% CI of NHC (**Table 2**).

A key question was whether all individuals with PD have a dysbiotic gut microbiome. To answer this question, we needed an operational definition of non-dysbiotic. We defined non-dysbiotic per feature as being well within the norm of NHC range, i.e., below the mean of NHC if the feature is elevated in PD, and above the mean if a feature is reduced in PD. When considering all six features, a PD person was designated as not having a dysbiotic microbiome only if their relative abundance for the five elevated features were all at or below the mean of NHC, and their relative abundance for reduced fiber degrading feature was at or greater than the mean in NHC.

## **Results**

Not all PD metagenomes are dysbiotic, and not all dysbiotic microbiomes have the same features.

Among 490 individuals with PD studied, 392 (80%) had at least one dysbiotic feature (**Figure 3a**). 98 (20%) did not have any dysbiotic feature defined as being outside the 95% CI of NHC. Using the more cautious definition of non-dysbiotic, i.e. elevated features being at or below the NHC mean and reduced features at or above the NHC mean, 76 (16%) of PD microbiomes were not dysbiotic. The patients without a dysbiotic microbiome can be identified and excluded from microbiome-based therapeutics; doing so will boost power and odds of success of clinical trials, and in clinical setting, will spare these patients unnecessary trial and error in finding the right treatment.

Severe reduction in fiber-degrading bacteria was seen in 333 of 490 of PD patients (68%) (**Figure 3a**). Among the 333 low fiber-degraders, only 96 had no other dysbiotic features (**Figure 3b**), hence 71% (=(333-96)/333) of patients with low fiber-degraders had high levels of at least one other dysbiotic feature. Thus, while deficiency of fiber degraders is very common, only 20% (=96/490) of PD patients had low fiber-degraders as their sole feature. This suggests that while fiber treatment would be beneficial for majority of patients, a subset would stand to benefit the most from fiber, while others may need treatment for their other dysbiotic features as well.

Features that are elevated in PD were found in subsets of patients: high levels of opportunistic pathogens was detected in 66 (13%) of the 490 PD, *Bifidobacterium* in 161 (33%), *Lactobacillus* 

in 103 (21%), *Streptococcus* and *Actinomyces* in 94 (19%), and *E. coli* and *Klebsiella* in 86 (18%). To demonstrate utility of the biomarker, consider *E. coli* which has been linked to pathobiology of PD. *E. coli* encodes curli, an amyloid that induces alpha-synuclein aggregation in mice <sup>12,13</sup>. Alpha-synuclein aggregation is a pathogenic hallmark of PD. Moreover, *E. coli* and genes that encode and regulate curli production are elevated in PD gut <sup>9</sup>. Should a drug be developed against *E. coli* or curli, it will likely have a far better odds of success in clinical trial if patients were chosen from the 18% that have high levels of *E. coli* and curli.

There is some overlap across the groups shown in **Figure 3a**, because these features are not mutually exclusive. For example, as shown in **Figure 3b**, among the 66 patients with high opportunistic pathogens, 33 (50%) also had high *Bifidobacteria*, 15 (23%) had high *Lactobacillus*, 18 (27%) had high *Streptococcus* and *Actinomyces*, 13 (20%) had *E. coli* and *Klebsiella*, and 57 (86%) had low fiber degraders. These data suggest that at the present time, with fiber and FMT being the only microbiome-based treatments, the most rational option for treating the patients who have a severely dysbiotic microbiome is cleansing the microbiome with antibiotics followed by FMT, excluding those without dysbiosis and those with only low fiber-degraders. We are not advocating for FMT or any treatment modality per se, rather, pointing out the utility of biomarkers in designing a study as well as choosing the patients to study and treat.

#### Application of the biomarker tool

Defining the features of interest and setting abundance thresholds to define dysbiotic/non-dysbiotic in a healthy population will constitute the reference dataset for this biomarker tool. To determine the composition of the metagenome of a patient will entail obtaining a stool sample, DNA extraction, sequencing, bioinformatic processing and taxonomic assignment of sequences, and calculating relative abundances of the microbial features. The patient's relative abundances for the features of interest are then compared to the reference dataset to determine if they are dysbiotic (**Figure 1**).

## **Discussion**

Here, we introduced a microbiome-based biomarker tool to guide patient selection for clinical trials and to serve as companion diagnostic for personalized treatments. With this tool, we can "see" if and what is dysbiotic in an individual and act accordingly. The method is applicable for

any patient at any stage of disease. The tool can be easily modified (by redefining features and adjusting thresholds) as the field advances, and to meet varying needs of different studies. Here, we demonstrated the development and the potential utility of the tool for identifying subtypes of PD based on their microbiome features. The concept is generalizable to any disease with a microbiome component.

224

225

226

227

228

229230

231

232

233

234235

236

237

238239

240

241

242

243

244

245

246

247248

249

250

251

252

253

254

255

256

257

Treating a dysbiotic microbiome can potentially be disease modifying, which has been an elusive goal in PD field. Functional inference of human data and experiments in mice indicate dysbiotic features of PD microbiome contribute to several disease mechanisms, including alphasynuclein aggregation which is at the core of PD pathology, disrupted neuro-signaling, and inflammation <sup>9,13,14</sup>. It is therefore reasonable to work towards microbiome-based therapies that could halt disease progression. As we learn which features are causal and which result from disease (an active area of research), microbiome-based biomarkers will be useful for identifying pathogenic dysbiosis early to prevent disease before onset.

Microbiome-based treatments under consideration for PD include prebiotics (e.g., fiber supplements), probiotics (beneficial bacteria packaged and marketed direct to consumer), FMT, and next generation therapeutics that are targeted to a specific feature (e.g., small molecules, phage, CRSPR-Cas9). The microbiome-based biomarkers described here can serve as companion diagnostic for all treatment modalities. Take fiber supplementation for example, which is safe and likely beneficial for everyone. We show here that indeed, the majority of PD patients have severely depleted levels of fiber-degrading bacteria. Increasing fiber intake is effectively feeding these bacteria and causing them to grow and multiply, and it has shown promise in an early clinical trial with newly diagnosed PD patients <sup>27</sup>. The value of coupling biomarkers with fiber treatment is in identifying patients who, in addition to being low on fiberdegraders, have elevated levels of harmful pathogenic bacteria, which is an important consideration both for patient selections for clinical trials and for treating the individuals. As for probiotics on the market, most are composed of "beneficial" species of Bifidobacteria and/or Lactobacillus, which ironically, are highly elevated in PD. The value of the biomarker in this case is to avoid supplementation that is counter indicated. FMT is showing promise for PD <sup>28</sup>, but it carries risks concerning safety and compatibility of donor sample with host environment. Using biomarkers, unnecessary FMT can be avoided, sparing the patients who do not have a dysbiotic microbiome and those whose only problem is low fiber-degraders. Targeted treatments could replace the need for FMT, and they too would benefit from a companion diagnostic. For

example, for a treatment targeted to abolish the opportunistic pathogens, the biomarker can identify the 13% of patients who would be the best candidates.

Currently, we do not know if alleviating one dysbiotic feature would restore homeostasis to the rest of the microbiome, and what that central feature might be. Consumption of fiber is the safest and simplest treatment. In a clinical trial performed on 20 newly diagnosed PD patients, treatment with fiber increased the abundance of fiber-degrading bacteria and production of short chain fatty acids and resulted in shifts in the microbiome community <sup>27</sup>. Fiber-degrading species are in the center of the Firework with tight positive and negative correlations to several PD-associated species (**Figure 2**). It is therefore plausible that fiber treatment, aimed to increase the abundance of fiber-degrading bacteria, may restore equilibrium to PD-associated species that map to the center of Firework and are either positively or negatively correlated with fiber-degraders. However, while possible, it is less likely that fiber treatment alone would eliminate overabundance of opportunistic pathogens, for example, considering that opportunistic pathogens are a dense isolated cluster with no connection to fiber-degrading species.

Profiling the patients' metagenome and comparing them to the reference dataset will show where they fall in the spectrum of dysbiosis. This concept, and the proposed method, holds true regardless of feature, disease, or dataset. However, the relative abundances of the features and therefore the range and thresholds for defining dysbiosis may differ across populations. Hence, it is important that the reference dataset is from the same source population as patients. Here, we used a cohort of neurologically healthy older adults from Birmingham, Alabama in United States for our reference dataset, as our patients are also from Birmingham. There are regional variation in microbiome, reflecting cultural, dietary, socioeconomic, and geographic influences. Despite regional variations, the main PD-associated features are robust and reproducible 9-11,32. Even so, the relative abundances, and hence the thresholds for defining dysbiosis, may still vary across populations. Not every investigator can amass hundreds of controls to investigate population-specific abundances to set their thresholds. This impediment will be overcome soon by current efforts to collect all data generated and made public. These collaborative global efforts are aimed at meta-analyses, a by-product of which will be open-access to well-curated datasets from across the world that can be used as reference datasets to generate populationspecific thresholds for biomarkers and companion diagnostics.

### **Data availability**

292

293

294

295

296

297298

299

300

301

302

303

304

305

306 307

308

309

310

311 312

313

314

315

316 317

318 319

320

321

322

323

324

The datasets used for biomarker development are openly public with no restrictions [https://www.nature.com/articles/s41467-022-34667-x]. The raw metagenomic sequences and accompanying metadata are at the NCBI SRA under BioProject ID PRJNA834801 [https://www.ncbi.nlm.nih.gov/bioproject/834801], and post-QC and post taxonomic profiling data are on Zenodo [https://zenodo.org/record/7246185]. **Acknowledgements** This work was supported by The Strain Endowed Chair in Parkinson's Disease to the University of Alabama at Birmingham (HP) and Aligning Science Across Parkinson's [ASAP-020527] through the Michael J. Fox Foundation for Parkinson's Research (MJFF) (HP, TRS, CFM). For the purpose of open access, the authors have applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission. Opinions, interpretations. conclusions, and recommendations are those of the authors and are not necessarily endorsed by the funding agencies. **Author contribution** This is a collaborative team (genomics (HP), microbiology (TRS), statistics (CFM)). The lead/corresponding author (HP) conceptualized and developed the method. HP drafted the manuscript and all authors contributed to revision and approved the final version. **Competing interest** HP has intellectual property pending on Personalized Microbiome-Based Therapies, Serial No.: 63/571,787; Filing Date: March 29, 2024. TRS is a co-inventor on intellectual property related to a small molecule microbiome-based therapy - US Patent 11,707,493 and 11,147, 792. References 1 Collaborators, G. B. D. P. s. D. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17, 939-953 (2018). https://doi.org:10.1016/S1474-4422(18)30295-3 2 Obeso, J. A. et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord 32, 1264-1310 (2017). https://doi.org:10.1002/mds.27115

325	3	Braak, H., Rub, U., Gai, W. P. & Del Tredici, K. Idiopathic Parkinson's disease: possible
326		routes by which vulnerable neuronal types may be subject to neuroinvasion by an
327		unknown pathogen. J Neural Transm (Vienna) 110, 517-536 (2003).
328		https://doi.org:10.1007/s00702-002-0808-2
329	4	Horsager, J. et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging
330		case-control study. Brain 143, 3077-3088 (2020). https://doi.org:10.1093/brain/awaa238
331	5	Holmqvist, S. et al. Direct evidence of Parkinson pathology spread from the
332		gastrointestinal tract to the brain in rats. Acta Neuropathol 128, 805-820 (2014).
333		https://doi.org:10.1007/s00401-014-1343-6
334	6	Breen, D. P., Halliday, G. M. & Lang, A. E. Gut-brain axis and the spread of alpha-
335		synuclein pathology: Vagal highway or dead end? Mov Disord 34, 307-316 (2019).
336		https://doi.org:10.1002/mds.27556
337	7	Kim, S. et al. Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to
338		the Brain Models Parkinson's Disease. Neuron 103, 627-641 e627 (2019).
339		https://doi.org:10.1016/j.neuron.2019.05.035
340	8	Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. Nat Rev
341		Microbiol 19, 55-71 (2021). https://doi.org:10.1038/s41579-020-0433-9
342	9	Wallen, Z. D. et al. Metagenomics of Parkinson's disease implicates the gut microbiome
343		in multiple disease mechanisms. Nat Commun 13, 6958 (2022).
344		https://doi.org:10.1038/s41467-022-34667-x
345	10	Romano, S. et al. Meta-analysis of the Parkinson's disease gut microbiome suggests
346		alterations linked to intestinal inflammation. NPJ Parkinsons Dis 7, 27 (2021).
347		https://doi.org:10.1038/s41531-021-00156-z
348	11	Toh, T. S. et al. Gut microbiome in Parkinson's disease: New insights from meta-
349		analysis. Parkinsonism Relat Disord 94, 1-9 (2022).
350		https://doi.org:10.1016/j.parkreldis.2021.11.017
351	12	Chen, S. G. et al. Exposure to the Functional Bacterial Amyloid Protein Curli Enhances
352		Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans. Sci
353		Rep 6, 34477 (2016). https://doi.org:10.1038/srep34477
354	13	Sampson, T. R. et al. A gut bacterial amyloid promotes alpha-synuclein aggregation and
355		motor impairment in mice. Elife 9 (2020). https://doi.org:10.7554/eLife.53111
356	14	Sampson, T. R. et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a
357		Model of Parkinson's Disease. Cell 167, 1469-1480 e1412 (2016).
		( )

359	15	Matheoud, D. et al. Intestinal infection triggers Parkinson's disease-like symptoms in
360		Pink1(-/-) mice. <i>Nature</i> <b>571</b> , 565-569 (2019). <a href="https://doi.org:10.1038/s41586-019-1405-y">https://doi.org:10.1038/s41586-019-1405-y</a>
361	16	Radisavljevic, N. et al. Effects of Gut Microbiota Alterations on Motor, Gastrointestinal,
362		and Behavioral Phenotype in a Mouse Model of Parkinson's Disease. J Parkinsons Dis
363		<b>12</b> , 1479-1495 (2022). <a href="https://doi.org:10.3233/JPD-223165">https://doi.org:10.3233/JPD-223165</a>
364	17	Bhattarai, Y. et al. Role of gut microbiota in regulating gastrointestinal dysfunction and
365		motor symptoms in a mouse model of Parkinson's disease. <i>Gut Microbes</i> <b>13</b> , 1866974
366		(2021). https://doi.org:10.1080/19490976.2020.1866974
367	18	Sun, M. F. et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-
368		induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha
369		signaling pathway. Brain Behav Immun 70, 48-60 (2018).
370		https://doi.org:10.1016/j.bbi.2018.02.005
371	19	Zhao, Z. et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's
372		disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4
373		signaling pathway through the microbiota-gut-brain axis. <i>Microbiome</i> <b>9</b> , 226 (2021).
374		https://doi.org:10.1186/s40168-021-01107-9
375	20	Bisht, R., Kaur, B., Gupta, H. & Prakash, A. Ceftriaxone mediated rescue of nigral
376		oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
377		Neurotoxicology 44, 71-79 (2014). https://doi.org:10.1016/j.neuro.2014.05.009
378	21	Du, Y. et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the
379		MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98, 14669-14674 (2001).
380		https://doi.org:10.1073/pnas.251341998
381	22	Pu, Y. et al. Antibiotic-induced microbiome depletion protects against MPTP-induced
382		dopaminergic neurotoxicity in the brain. Aging (Albany NY) 11, 6915-6929 (2019).
383		https://doi.org:10.18632/aging.102221
384	23	Kaur, B. & Prakash, A. Ceftriaxone attenuates glutamate-mediated neuro-inflammation
385		and restores BDNF in MPTP model of Parkinson's disease in rats. Pathophysiology 24,
386		71-79 (2017). https://doi.org:10.1016/j.pathophys.2017.02.001
387	24	Abdel-Haq, R. et al. A prebiotic diet modulates microglial states and motor deficits in
388		alpha-synuclein overexpressing mice. Elife 11 (2022).
389		https://doi.org:10.7554/eLife.81453
390	25	Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. Nat Rev Microbiol 20,
391		365-380 (2022). https://doi.org:10.1038/s41579-021-00667-9

392	26	Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease -
393		from basic research to the clinic. Nat Rev Neurol 18, 476-495 (2022).
394		https://doi.org:10.1038/s41582-022-00681-2
395	27	Hall, D. A. et al. An open label, non-randomized study assessing a prebiotic fiber
396		intervention in a small cohort of Parkinson's disease participants. Nat Commun 14, 926
397		(2023). https://doi.org:10.1038/s41467-023-36497-x
398	28	DuPont, H. L. et al. Fecal microbiota transplantation in Parkinson's disease-A
399		randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol 14,
400		1104759 (2023). https://doi.org:10.3389/fneur.2023.1104759
401	29	Cheng, Y. et al. Efficacy of fecal microbiota transplantation in patients with Parkinson's
402		disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes
403		15, 2284247 (2023). https://doi.org:10.1080/19490976.2023.2284247
404	30	Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R. & Ifergane, G. Fecal microbiota
405		transplant as a potential treatment for Parkinson's disease - A case series. Clin Neurol
406		Neurosurg 207, 106791 (2021). https://doi.org:10.1016/j.clineuro.2021.106791
407	31	Xue, L. J. et al. Fecal microbiota transplantation therapy for Parkinson's disease: A
408		preliminary study. Medicine (Baltimore) 99, e22035 (2020).
409		https://doi.org:10.1097/MD.000000000022035
410	32	Wallen, Z. D. et al. Characterizing dysbiosis of gut microbiome in PD: evidence for
411		overabundance of opportunistic pathogens. NPJ Parkinsons Dis 6, 11 (2020).
412		https://doi.org:10.1038/s41531-020-0112-6
413		

Table 1. Six main dysbiotic features of PD gut microbiome

Feature	Species composition of feature	PD association	Number of connections	
Opp pathogens	Actinomyces turicensis	Increased as cluster	8	
Opp pathogens	Anaerococcus octavius	Increased as cluster	4	
Opp pathogens	Anaerococcus vaginalis	Increased as cluster	5	
Opp pathogens	Atopobium minutum	Increased as cluster	8	
Opp pathogens	Corynebacterium amycolatum	Increased as cluster	2	
Opp pathogens	Corynebacterium aurimucosum	Increased as cluster	2	
Opp pathogens	Finegoldia magna	Increased as cluster	7	
Opp pathogens	Gemella asaccharolytica	Increased as cluster	2	
Opp pathogens	Peptoniphilus harei	Increased as cluster	1	
Opp pathogens	Peptoniphilus lacrimalis	Increased as cluster	3	
Opp pathogens	Peptoniphilus sp HMSC062D09	Increased as cluster	7	
Opp pathogens	Porphyromonas asaccharolytica	Increased	6	
Opp pathogens	Porphyromonas sp HMSC065F10	Increased as cluster	11	
Opp pathogens	Porphyromonas uenonis	Increased as cluster	6	
Opp pathogens	Prevotella bergensis	Increased as cluster	1	
Opp pathogens	Prevotella buccalis	Increased as cluster	10	
Opp pathogens	Prevotella disiens	Increased as cluster	1	
Opp pathogens	Prevotella timonensis	ensis Increased as cluster		
Opp pathogens	Varibaculum cambriense	Increased as cluster	10	
Bifidobacteria	Bifidobacterium dentium	Increased	12	
Bifidobacteria	Bifidobacterium bifidum	Increased	3	
Bifidobacteria	Bifidobacterium breve	Increased	24	
Bifidobacteria	dobacteria Bifidobacterium gallinarum		14	
Bifidobacteria	Bifidobacterium longum	Increased	5	
Bifidobacteria	Bifidobacterium pullorum	Increased	12	
Bifidobacteria	Bifidobacterium saeculare	Increased	13	
Lactobacillus	Lactobacillus fermentum	Increased	14	
Lactobacillus	Lactobacillus gasseri	Increased	10	
Lactobacillus	Lactobacillus paragasseri	Increased	9	
Lactobacillus	tobacillus Lactobacillus salivarius		9	
Lactobacillus	actobacillus Lactobacillus reuteri		1	
Lactobacillus	acillus Lactobacillus rhamnosus		11	
Strepto / Actino	Actinomyces naeslundii	Increased	4	
Strepto / Actino	Actinomyces oris	Increased	16	
Strepto / Actino	Actinomyces sp HPA0247	Increased	3	
Strepto / Actino	Actinomyces sp oral taxon 448	Increased	3	
Strepto / Actino	Streptococcus anginosus group	Increased	10	

Strepto / Actino	Streptococcus mutans	Increased	13
Strepto / Actino	Streptococcus vestibularis	Increased	15
Strepto / Actino	Streptococcus lutetiensis	Increased	3
E. coli / klebsiella	Escherichia coli	Increased	5
E. coli / klebsiella	Klebsiella pneumoniae	Increased	3
E. coli / klebsiella	Klebsiella quasipneumoniae	Increased	3
Fiber-degraders	Blautia wexlerae	Decreased	17
Fiber-degraders	Blautia hansenii	Decreased	17
Fiber-degraders	Anaerostipes hadrus	Decreased	48
Fiber-degraders	Clostridium sp CAG 58	Decreased	27
Fiber-degraders	Eubacterium eligens	Decreased	47
Fiber-degraders	Eubacterium hallii	Decreased	52
Fiber-degraders	Eubacterium ramulus	Decreased	25
Fiber-degraders	Eubacterium rectale	Decreased	21
Fiber-degraders	Eubacterium sp CAG 38	Decreased	22
Fiber-degraders	Faecalibacterium prausnitzii	Decreased	59
Fiber-degraders	Fusicatenibacter saccharivorans	Decreased	45
Fiber-degraders	Roseburia faecis	Decreased	21
Fiber-degraders	Roseburia intestinalis	Decreased	21
Fiber-degraders	Roseburia inulinivorans	Decreased	27
Fiber-degraders	Ruminococcus bicirculans	Decreased	33
Fiber-degraders	Ruminococcus lactaris	Decreased	12


We selected species that individually, or as a cluster, were significantly elevated or reduced in PD <sup>9</sup>, and assigned them to a "feature" according to the correlation in their abundances (connectivity, see **Figure 2**) and their taxonomic relatedness (members of same genus). Here, our aim was to demonstrate the method, for which we strived for a balance between capturing the most robust association with PD and reducing the complexity. Features can be redefined to accommodate the aims of the investigation.


Table 2. Defining dysbiotic

Feature	Relative abundance of feature in 234 NHC			Relative abundance of feature in 490 PD			N PD outside
	Mean	Upper 95% CI	Lower 95% CI	Mean	Upper 95% CI	Lower 95% CI	95% CI of NHC
Opp. pathogens	0.01%	0.01%	0.00%	0.10%	0.20%	0.00%	66
Bifidobacteria	2.06%	2.66%	1.47%	5.07%	5.98%	4.17%	161
Lactobacillus	0.11%	0.19%	0.04%	0.55%	0.74%	0.36%	103
Streptococcus / Actinomyces	0.19%	0.33%	0.06%	0.39%	0.54%	0.25%	94
E. coli / Klebsiella	1.47%	2.23%	0.72%	1.94%	2.44%	1.43%	86
Fiber-degraders	22.35%	23.88%	20.81%	15.29%	16.36%	14.22%	333

Each feature is composed of several species, as shown in **Table 1**. The relative abundance of each species in each individual was calculated as reported before <sup>9</sup> and can be found here <a href="https://zenodo.org/record/7246185">https://zenodo.org/record/7246185</a>. We calculated relative abundance of each feature in each neurologically healthy control (NHC) and individual with PD by summing the relative abundances of the species within the feature for that individual. We then calculated the mean and 95% confidence interval (CI) of the mean in the NHC and PD separately. We set the threshold for defining dysbiotic at the upper 95% CI of NHC for features that are elevated in PD, and at lower 95% CI of NHC for fiber-degraders that are reduced in PD. Last column is the number of PD patients, among 490 total, who were called dysbiotic for each feature. For example, in 161 of 490 PD patients, the relative abundance of *Bifidobacteria* was higher than 2.66% which was the upper 95% CI limit of NHC. Similarly, in 333 of 490 patients, the relative abundance of fiber-degrading bacteria was lower than 20.81% which was the lower 95% CI limit in NHC.

# **Building the reference dataset**





#### Figure 1. The method.

The concept is to develop a biomarker tool that will help us "see" if a person's microbiome is dysbiotic, and if so, what are their dysbiotic features. The goal is to optimize patient selection for clinical trials of microbiome-based studies, and upon approval, use it as diagnostic companion for personalized treatment. A reference dataset is built by obtaining the metagenomic profiles of a non-disease cohort that represents the same population as the persons to be studied or treated. Once this infrastructure is in place, one can pick any feature (from a microbial gene to species to polymicrobial clusters), calculate its relative abundance and confidence interval (CI) in the non-disease group, and set thresholds for defining dysbiotic and non-dysbiotic. Application entails obtaining the metagenomic profile of the individual of interest and comparing it to the non-disease population. Here, we selected 6 PD-associated features (each a polymicrobial cluster), 5 of which are elevated in PD, and one reduced in PD <sup>9</sup>. We set the threshold at 95%CI of the non-disease reference dataset. A person would be marked as dysbiotic for a feature if their relative abundance of that feature is above (for features that are elevated in PD) or below (for feature that are reduced) the 95%CI in non-disease population.




Figure 2. Fireworks

Polymicrobial clusters of species in PD gut microbiome. Pairwise correlation in relative abundances of all species detected in 490 unique PD gut metagenomes (i.e. 490 individuals with PD) was calculated and plotted (methods are described in Wallen et al <sup>9</sup>). Each circle (node) represents one species and the curved lines (edges) connect species whose relative abundance correlate with each other (at correlation |r|>0.2, permuted P<0.05). Here, we have highlighted PD-associated species that were selected for this study, denoting by color the 6 dysbiotic features (species within each feature are listed in **Table 1**):

Blue: Opportunistic pathogens (elevated in PD)

Red: fiber-degraders (reduced in PD)

Yellow: E. coli and Klebsiella (elevated in PD)


Green: *Bifidobacteria* (elevated in PD)

Orange: *Lactobacillus* (elevated in PD)

Purple: *Streptococcus* and *Actinomyces* (elevated in PD)


Grey: associated with PD, not selected as feature

Empty circle: not associated with PD



b

	Opp path	Bifido- bacteria	Lacto- bacillus	Strepto /Actino	E. coli / Klebsiella	Fiber- degraders
Opp Pathogens	66					
Bifidobacteria	33	161				
Lactobacillus	15	49	103			
Strepto / Actino	18	50	47	94		
E. coli/ Klebsiella	13	27	27	22	86	
Fiber-Degraders	57	135	88	81	69	333
No Others	5	18	5	5	9	96



## Figure 3. Subtyping PD by the dysbiotic features of the gut microbiome.

The total number of patients is 490. The total number of patients with a dysbiotic feature is 392 (=490-98). The number of patients with a given dysbiotic feature are given in a-c. Actual numbers are given so that percentages can be calculated with the desired denominator.

- (a) Proportion of PD patients with different dysbiotic features.
  - Elevated features: number of PD persons, among the 490, who had an abundance higher than upper limit of the 95% CI of the abundance in neurologically healthy control (NHC).
  - Reduced feature: number of PD persons, among the 490, who had an abundance lower than the lower limit of 95% CI of the abundance in NHC.
  - No detectable dysbiosis: 98 of 490 (20%) did not fall outside 95% CI of NHC for any feature. 76 of 490 (16%) of PD persons fit the more cautious definition of non-dysbiotic, whose abundances for every elevated feature (opportunistic pathogens, *Bifidobacteria*, *Lactobacillus*, *Streptococcus* and *Actinomyces* (Strepto/Actino), and *E. coli/Klebsiella*) was below the NHC mean, and their abundance for reduced fiber-degrading bacteria was above the NHC mean.
- (b) Pairwise overlap in features, n=number of patients, from 490, who have the two specified features. The total for six features (the diagonal) is 843, nearly double the number of 490 subjects, because features do co-occur in an individual. For example, 66 of 490 subjects had elevated (>95%Cl of NHC) levels of opportunistic pathogens, among them, 33 (50%) also had elevated Bifidobacteria. Or the example in the text, 71% (=(333-96)/333) of low fiber-degraders had high level of at least one other feature.
- (c) Overlap across the 5 features that are elevated in PD (fiber-reducers not included for legibility). For example, 19 subjects have elevated levels (>95%Cl of NHC) of *Streptococcus* and *Actinomyces* only, another 2 subjects have high *Streptococcus* and *Actinomyces* and high opportunistic pathogens, another 3 have high *Streptococcus* and *Actinomyces*, high opportunistic pathogens, and high *Lactobacillus*, etc.